British Journal of Clinical Pharmacology

Article	Citations
	67
Issue Information	66
Issue Highlights	63
Effect of oral clonidine on pain reduction in patients with opioid use disorder in the emergency department: A randomized clinical trial	56
Pharmacokinetics, safety and efficacy study in pregnancy and existing cumulative data/evidence to support clinical use and labelling of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in pre	55
Impact of codeine rescheduling on prescribing of codeine and other opioids: Interrupted time series analyses using Australian general practice data	55
Selected Abstracts from Pharmacology 2024	55
A narrative review of vaccine pharmacovigilance during mass vaccination campaigns: Focus on myocarditis and pericarditis after COVID‐19 mRNA vaccination	54
Model‐based dosing optimization and therapeutic drug monitoring practices of teicoplanin in patients with complicated or non‐complicated methicillin‐resistant staphylococcus aureus infection	52
Case report: Dolutegravir dosing post‐Roux‐en‐Y gastric bypass surgery	51
Letter to the editor concerning the article: ‘The impacts of undetected nonadherence in phase II, III and post‐marketing clinical trials: An overview’	49
Drug reaction with eosinophilia and systemic symptoms induced by paclitaxel, a rare combination	49
Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study	48
Intranasal vitamin B12 administration in elderly patients: A randomized controlled comparison of two dosage regimens	41
Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects	39
Cardiovascular events of Bruton's tyrosine kinase inhibitors: A real‐world study based on the United States Food and Drug Administration Adverse Event Reporting System database	39
Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real‐world data and simulated data	39
Therapeutic drug monitoring of thiopurines: Effect of reduced 6‐thioguanine nucleotide target levels in inflammatory bowel disease patients	38
Triple antithrombotic therapy and dual therapy – What is the evidence base?	38
Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model	38
Antidepressants are not safe during pregnancy and in women of child‐bearing age	36
Postoperative ileus after digestive surgery: Network meta‐analysis of pharmacological intervention	36
Prospective evaluation of pregnancy outcomes after gestational exposure to prazosin	35
Comparison of a polypharmacy‐based scale with Charlson comorbidity index to predict 6‐month mortality in chronic complex patients after an ED visit	35
Lemborexant levels in breast milk after single doses in healthy, lactating women	34

Modelling the progression of illicit substance use patterns from real‐world evidence	34
Does coprescribing nonsteroidal anti‐inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism?	32
Serum uric acid lowering mediated by glucagon‐like peptide‐1 receptor agonists: Emerging considerations	31
Epidural methadone and morphine pharmacokinetics and clinical effects in healthy volunteers: A randomized, crossover‐design trial	31
Design of a pharmacokinetic/pharmacodynamic model for administration of low dose peripheral norepinephrine during general anaesthesia	30
Pregabalin poisoning: Evaluation of dose‐toxicity relationship	30
Analysis of factors influencing the relationship between voriconazole plasma concentrations and adverse effects in a paediatric population	30
Older adults' adherence to medications and willingness to deprescribe: A substudy of a randomized clinical trial	29
Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID‐19 Requiring invasive ventilation Meta‐Trial (CHARTER‐MT): Protocol and statistical analysis plan for an investigat	29
Potential drug–drug interactions when managing status epilepticus patients in intensive care: A cohort study	29
Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings	28
A first‐in‐human study of the anti‐inflammatory profibrinolytic TMS‐007, an SMTP family triprenyl phenol	28
Chemometrics as a valuable tool for evaluating interactions between antiretroviral drugs and food	28
Effects of intraoperative low‐dose esketamine on postoperative pain after vestibular schwannoma resection: A prospective randomized, double‐blind, placebo‐controlled study	28
Superiority of ceftazidime off‐label high‐dose regimen in PK/PD target attainment during treatment of extensively drug‐resistant Pseudomonas aeruginosa infections in cancer patients	27
Genetic biomarkers of methotrexate response and safety in Crohn's disease: Data from the Spanish ENEIDA registry	27
Health technology assessment of paediatric medicines: European landscape, challenges and opportunities inside the conect4children project	27
Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients	27
Insights from a pharmacometric analysis of HDMTX in adults with cancer: Clinically relevant covariates for application in precision dosing	26
Adverse events of alpelisib: A postmarketing study of the World Health Organization pharmacovigilance database	26
Acalabrutinib CYP3A‐mediated drug–drug interactions: Clinical evaluations and physiologically based pharmacokinetic modelling to inform dose adjustment strategy	25
Population pharmacokinetic modelling of prednisolone in systemic lupus erythematosus patients: Analysis of exposure and disease activity	24
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers	24
Opioid‐related deaths and their counterpart by occurrence era, age group and coimplicated drugs: Scotland vs. England and Wales	24
Treatment with methylphenidate and the risk of fractures among children and young people: A systematic review and self‐controlled case series study	23
	23
c4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper	22
Unravelling sources of variability on rocuronium pharmacokinetics: Implications for prolonged recovery in older patients	22
From statistical inference to machine learning: A paradigm shift in contemporary cardiovascular pharmacotherapy	22
Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite	22
	22
Issue Highlights	21
Medication compliance aids unpackaged: A national survey	21
Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach	21
Predicting outcomes for spinal muscular atrophy: When the diagnosis no longer means what it used to mean	21
Issue Information	21
The trajectory of pharmacometrics to support drug licensing and labelling	21
Prevalence of potentially inappropriate medications among newly treated patients with type 2 diabetes in UK primary care	21
Impact of pre‐emptive rapid testing for glucose‐6‐phosphate dehydrogenase deficiency prior to rasburicase administration at a tertiary care centre: A retrospective study	21
Out‐of‐hospital cardiac arrest and differential risk of cardiac and non‐cardiac QT‐prolonging drugs in 37 000 cases	21
Using soluble urokinase plasminogen activator receptor to stratify patients for medication review in the emergency department	21
Validation of self‐reported medication use applying untargeted mass spectrometry‐based metabolomics techniques in the Rhineland study	20
Impact of CYP2D6*2A, CYP2D6*4 and CYP3A5*3 genetic polymorphisms on Bisoprolol peak concentration and clinical response in acute coronary syndrome patients	20
Hospital pharmacists' opinions on a risk prediction tool for medication‐related harm in older people	20
Long‐term bisphosphonate therapy and atypical femoral fracture: Can you have too much of a good thing?	20
Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant	20
Coping with COVID: Preparing prescribers during the pandemic	20
In utero exposure to antiretroviral drugs and pregnancy outcomes: Analysis of the French ANRS pharmacovigilance database	20
Performance of the ChatGPT large language model for decision support in community pharmacy	20
A pharmacometrics model to define docetaxel target in early breast cancer	20

Risk of infection from glucocorticoid and methotrexate interaction in patients with rheumatoid arthritis using biologics: A retrospective cohort study	19
Management of serotonin syndrome (toxicity)	19
Transgender people in clinical trials of drugs and biologics: An analysis of ClinicalTrials.gov from 2007 to 2023	19
Spotlight commentary: The value of spontaneous reporting systems to detect (the lack of) clinically relevant drug–drug interactions in clinical practice	19
Incorporating the One Health Philosophy into pharmacovigilance: Ecopharmacovigilance	19
Comparison of the efficacy and safety of standard‐ and high‐dose daptomycin: A systematic review and meta‐analysis	19
	18
Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach	18
The impact of a preprescribing formative assessment on learning in final‐year medical students using hospital inpatient electronic prescribing systems	18
Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing	18
The effects of saffron (Crocus sativus L.) in conjunction with concurrent training on body composition, glycaemic status, and inflammatory markers in obese men with type 2 diabetes m	18
Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data	18
Correction	18
Metamizole induces voriconazole metabolism and results in subtherapeutic voriconazole concentrations	18
Factors affecting creatine phosphokinase elevation during daptomycin therapy using a combination of machine learning and conventional methods	18
Dose‐dependent glucosuria of DWP16001, a novel selective sodium–glucose cotransporter‐2 inhibitor, in healthy subjects	18
Issue Highlights	17
Population modelling of nilotinib exposure vs. longitudinal BCR::ABL1 response in patients with chronic phase chronic myeloid leukaemia using a semimechanistic disease model	17
Spotlight commentary: Innovations in clinical trials	17
Issue highlights	17
	17
Adverse events associated with monoclonal antibodies used for treatment of COVID‐19: A systematic review and meta‐analysis	17
Concentration–response relationships of dolutegravir and efavirenz with weight change after starting antiretroviral therapy	17
The efficacy of hydroxychloroquine in paediatric chronic immune thrombocytopenia: A retrospective cohort study	17
A review on the role of extrapolation as basis for paediatric marketing authorization applications of medicines in the EU	17
Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis	17
Optimization of vigabatrin dosage in children with epileptic spasms: A population pharmacokinetic approach	16
Physiologically based pharmacokinetic model for oxcarbazepine active metabolite to predict pharmacokinetics in paediatric patients with renal impairment and adjust dosages	16
Paliperidone poisoning and measurable plasma concentrations 2.5 years after last administered dose: A case report	16
Effect of glucagon‐like peptide‐1 receptor agonists on renal function: A meta‐analysis of randomized controlled trials	16
Oral paltusotine, a nonpeptide selective somatostatin receptor 2 agonist: Mass balance, absolute bioavailability and metabolism in healthy participants	16
Ethical concern regarding the UK PANORAMIC COVID‐19 trial	16
Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time‐trend analysis from 2004 to 2021	16
Cabotegravir PopPK analysis of adults and adolescents living with HIV/at risk for HIV receiving prep	16
A phase I study to evaluate the safety, tolerance and pharmacokinetics of anti‐Shiga toxin hyperimmune equine F (ab′)2 fragments in healthy volunteers	16
Single‐ascending dose and food effect studies to assess safety and pharmacokinetics of ainuovirine, a novel non‐nucleoside reverse transcriptase inhibitor, for treatment of HIV‐1 infection	16
Association of renin–angiotensin–aldosterone system inhibition with Covid‐19 hospitalization and all‐cause mortality in the UK biobank	16
Challenging times: Delivering gene therapies and an opportunity for shared learning	16
A single once daily ABC/DTG/3TC tablet predicts safe and effective exposures in children 3 to <6 kg	16
Assessing the anticholinergic cognitive burden classification of putative anticholinergic drugs using drug properties	16
Scalability of effective adherence interventions for patients using cardiovascular disease medication: A realist synthesis‐inspired systematic review	15
Association of state‐level prescription drug monitoring program implementation with opioid prescribing transitions in primary care in Australia	15
Physostigmine should be used more readily for antimuscarinic toxicity: CON	15
Population pharmacokinetics of sublingually administered tacrolimus in infants and young children with liver transplantation	15
Variability in the prevalence of inappropriate medication use among older adults: A review highlighting the importance of screening methods and database types	15
Population pharmacokinetics of cabotegravir following administration of oral tablet and long‐acting intramuscular injection in adult HIV‐1‐infected and uninfected subjects	15
Adverse event profiles of PCSK9 inhibitors alirocumab and evolocumab: Data mining of the FDA adverse event reporting system	15
Hyperbaric oxygen should not be used routinely for carbon monoxide poisoning	15
Issue Highlights	15
Evaluation of adherence to abiraterone therapy in prostate cancer patients based on a population pharmacokinetic model	15
Concomitant use of statins and sodium‐glucose co‐transporter 2 inhibitors and the risk of myotoxicity reporting: A disproportionality analysis	14
Epigenetic modifications in drug‐induced liver injury: A systematic review	14
Issue Highlights	14
Assessment and evaluation of prescribing competences: A systematic review and recommendations	14
Infliximab‐induced symmetrical drug‐related intertriginous and flexural exanthema (SDRIFE) in a patient with ulcerative colitis	14
Assessing the feasibility of infusing slow normal saline through a three‐metre‐longline to maintain patency of a peripheral venous cannula: A pilot study	14
Cefuroxime axetil dosing regimens and probability of target attainment in adults and children	14
Sodium–glucose cotransporter 2 inhibitor increases risk of urinary tract infection: Evidence from mendelian randomization and meta‐analysis	14
UK Prescribing Safety Assessment (PSA): The development, implementation and outcomes of a national online prescribing assessment	14
Do we become better prescribers after graduation: A 1‐year international follow‐up study among junior doctors	14
Precision therapy with quinidine of KCNT1‐related epileptic disorders: A systematic review	14
Ocular disorders associated with PCSK9 inhibitors: A pharmacovigilance disproportionality analysis	14
Solanidine‐derived CYP2D6 phenotyping elucidates phenoconversion in multimedicated geriatric patients	14
Sustainable medicines use in clinical practice: A clinical pharmacological view on eco‐pharmaco‐stewardship	14
Anticoagulation intensity and outcomes among southeast‐Asians with moderate‐to‐severe mitral valve stenosis	14
Preclinical pharmacokinetics of novel long‐acting tenofovir alafenamide/bictegravir solid injectable in rats	14
Issue Information	13
Correction to “Incidence and trend of cardiac events among children and young adults exposed to psychopharmacological treatment (2006–2018): A nationwide register‐based study”	13
Para‐aminosalicylic acid significantly reduced tenofovir exposure in human subjects: Mismatched findings from in vitro to in vivo translational research	13
Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam	13
	13
Issue Information	13
Application of immunocapture and nanoflow LC–MS/MS to overcome the barriers to the quantitation of oxytocin in plasma of women in third stage labour	13
Inter‐regional pharmacokinetics and exposure–response analyses of belimumab in patients with system lupus erythematosus	13
Appraising the visibility, relevance and impacts of clinical pharmacology	13
Effect of lemborexant on pharmacokinetics of clozapine: A potential drug–drug interaction mediated by time‐dependent inhibition of CYP3A4	13
Drug–drug interactions between gender‐affirming hormone therapy and antiretrovirals for treatment/prevention of HIV	13
Antidepressant prescribing patterns and adverse events following introduction of a National Prescribing Indicator to monitor dosulepin usage in Wales	12
	12
Learning from remote decentralised clinical trial experiences: A qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders	12

Assessment of the safety, pharmacokinetics and pharmacodynamics of GSK3335065, an inhibitor of kynurenine monooxygenase, in a randomised placebo‐controlled first‐in‐human study in healthy volunteers	12
Results of the first international quality control programme for oral targeted oncolytics	12
Beta‐thalassemia and the advent of new interventions beyond transfusion and iron chelation	12
Population pharmacokinetic/target engagement modelling of tozorakimab in healthy volunteers and patients with chronic obstructive pulmonary disease	12
Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing	12
Sustainable medicines development and use: Challenges and opportunities in the sustainable production of active pharmaceutical ingredients	12
Switching of oral anticoagulants in patients with nonvalvular atrial fibrillation: A narrative review	12
Pro: Oximes should be used routinely in organophosphate poisoning	12
Pharmacoethics and pregnancy: Overcoming the therapeutic orphan stigma	12
Positive correlation between organic anion transporter 1B function indicated by plasma concentration of coproporphyrin‐I and blood concentration of cyclosporin A in real‐world patients	12
Risk of out‐of‐hospital cardiac arrest in antidepressant drug users	12
Paediatric and obstetrical pharmacology – Pushing the frontier forward	12
Assessment of the influence of body fat indices on antihypertensive drug responses	12
Identification and comparison of sex‐specific serious adverse drug reactions in spontaneous reports and systematically collected reports (ADRED)	12
Issue Information	12
Evaluating the pharmacotherapy of tirzepatide in patients with type 2 diabetes: The consideration of systemic metabolism	12
Trends in opioid prescribing in Scandinavian countries from 2010 to 2023: Insights from multi‐metric evaluation	12
Addressing the challenges of novel therapies in rare diseases with mechanistic perspectives: Missed opportunities or the way forward?	12
Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS‐CoV‐2	12
COVID‐19 severity gradient differentially dysregulates clinically relevant drug processing genes in nasopharyngeal swab samples	12
Comparing regulatory guidance on risk minimization/mitigation and the Reporting recommendation Intended for pharmaceutical Risk Minimization Evaluation Studies checklist	12
A crossover study evaluating the sex‐dependent and sensitizing effects of sleep deprivation using a nociceptive test battery in healthy subjects	12
Changes in antiepileptic drug prescriptions over a decade in childbearing women in Lombardy region, Italy	12
Adherence levels and patterns for multiple cardiac medications prescribed to patients with incident atrial fibrillation events	12
Sub‐ and supratherapeutic efavirenz plasma concentrations with risk for HIV therapy failure are mainly genetically explained in Ugandan children: The prospective GENEFA cohort study	12
Maternal exposure to folate antagonists and susceptibility to congenital heart disease in offspring: A systematic review and meta‐analysis	12
Pharmacokinetic‐pharmacodynamic (PK/PD) modelling of cotadutide effect in patients with chronic kidney disease and type 2 diabetes mellitus	12
Isoniazid level and flu‐like symptoms during rifapentine‐based tuberculosis preventive therapy: A population pharmacokinetic analysis	12
Investigation of the absolute bioavailability, mass balance, metabolism, and excretion of the cholesterol 24‐hydroxylase inhibitor soticlestat in healthy volunteers	12
Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study	12
Risk of out‐of‐hospital cardiac arrest in patients with epilepsy and users of antiepileptic drugs	12
Prescriptions of anti‐reflux drugs in neonatology and neonatal intensive care units: A large multicentre observational study (2014–2022)	12
A population pharmacokinetic–pharmacodynamic model evaluating efficacy of nalbuphine extended‐release in patients with prurigo nodularis	12
Access to palivizumab among children at high risk of respiratory syncytial virus complications in English hospitals	11
Issue Information	11
A new population pharmacokinetic model for recombinant factor IX‐Fc fusion concentrate including young children with haemophilia B	11
Pharmacokinetics of molnupiravir and favipiravir in plasma separation cards from patients with COVID‐19: Agile CST‐2 and CST‐6	11
Evaluation of acquired antithrombin deficiency in paediatric patients supported on extracorporeal membrane oxygenation	11
Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women	11
A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers	11
Association between polymorphisms of the VKORC1 and CYP2C9 genes and warfarin maintenance dose in Peruvian patients	11
Potential drug–drug interactions due to concomitant medicine use among people living with HIV on antiretroviral therapy in Australia	11
The effect of chemotherapy on the exposure–response relation of abiraterone in metastatic castration‐resistant prostate cancer	11
Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants	11
Spotlight commentary: New Frontiers in pneumonia treatment	11
Medication adherence and hospitalizations in older patients with coronary heart disease in Vietnam	11
Identifying and addressing pill aversion in adults without physiological‐related dysphagia: A narrative review	11
Favipiravir pharmacokinetics in saliva, tears and nasal secretions of hospitalized COVID‐19 patients following intravenous favipiravir administration	11
Addition of direct oral anticoagulants to the World Health Organization model list of essential medicines for the treatment of atrial fibrillation: An African perspective	11
Population total and unbound pharmacokinetics and pharmacodynamics of ciprofol and M4 in subjects with various renal functions	11
Successful treatment of hepatitis C virus infection in patients on anti‐epileptics or mood stabilizers using pharmacokinetic enhancers	11
DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine‐based protocols	11
Population pharmacokinetics of rotigotine extended‐release microspheres for intramuscular injection in patients with early‐stage Parkinson's disease	11
Influence of gut bile acid composition on the glucose‐lowering effect and safety of metformin	11
Low‐dose amitriptyline: A potential therapeutic option for chronic pain in older people	11
Pharmacokinetics of YK‐1169 in healthy subjects and pharmacokinetic/pharmacodynamic analysis by Monte Carlo simulation	11
Nonchemotherapy drug‐induced cytopenias: A cost‐of‐illness study using the microcosting methodology based on real‐world data	11
Issue Information	11
Sustainable medicines development and use: Our collective responsibility for action to mitigate the natural world crisis	11
Mindfulness‐Oriented Recovery Enhancement: Implementing an evidence‐based intervention for chronic pain, opioid use, and opioid addiction in clinical settings	11
Killing several birds with one stone: A multi‐indication population pharmacokinetic model and Bayesian estimator for enteric‐coated mycophenolate sodium	11
Effects of ABCB1 polymorphisms on the transport of ponatinib into the cerebrospinal fluid in Japanese Philadelphia chromosome‐positive acute lymphoblastic leukaemia patients	11
Non‐compartmental and population pharmacokinetic analysis of dapsone in healthy NIGERIANS: A pilot study	11
Altered bile acid and coproporphyrin‐I disposition in patients with autosomal dominant polycystic kidney disease	11
Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study	10
Clinical validation of clinical decision support systems for medication review: A scoping review	10
Methodological issues in research on drug‐related admissions: A meta‐epidemiological review with focus on causality assessments	10
Effect of isotretinoin on CYP2D6 and CYP3A activity in patients with severe acne	10
Safe and supportive prescribing in transgender and non‐binary patients with cancer	10
Cytochrome P450 1A2 is the most important enzyme for hepatic metabolism of the metamizole metabolite 4‐methylaminoantipyrine	10
Issue Highlights	10
Off‐label and unlicensed medicine prescribing in university hospital paediatric wards in Finland: A prospective study	10
Issue Highlights	10
Population pharmacokinetic‐pharmacodynamic modelling of platelet time‐courses following administration of abrocitinib	10
Clinical pharmacology in adolescent transgender medicine	10
Local variation in low carbon footprint inhalers in pre‐COVID pandemic primary care prescribing guidelines for adult asthma in England and its potential impact	10
Developing an international concept‐based curriculum for pharmacology education: The promise of core concepts and concept inventories	10
Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: A case report	10
	10
Implementability of opioid deprescribing interventions at transitions of care: A scoping review	10
Efficacy and safety of tocilizumab versus standard care/placebo in patients with COVID‐19; a systematic review and meta‐analysis of randomized clinical trials	10
Multimethod quantitative benefit‐risk assessment of treatments for moderate‐to‐severe osteoarthritis	10
Concentrations of psychoactive substances in blood samples from non‐fatal and fatal opioid overdoses	10
Drug shortages. Part 1. Definitions and harms	10
Issue Information	10
Pharmacokinetic modelling to enable early attrition of repurposed antiviral drug combination candidates with a high likelihood of failure in COVID‐19	10
Twice neglected? Neglected diseases in neglected populations	9
‘Under pressure’: The role of therapeutic drug monitoring in the treatment of hypertension	9
Intramuscular cabotegravir and rilpivirine concentrations after switching from efavirenz‐containing regimen	9
Bioinformatics‐guided disproportionality analysis of sevoflurane‐induced nephrogenic diabetes insipidus using the FDA Adverse Event Reporting System database	9
Prevalence and management of drug interactions between nonsteroidal anti‐inflammatory drugs and antithrombotics in ambulatory care	9
Anthony Peck (1933–2021)	9
Impact of P‐glycoprotein and/or CYP3A4‐interacting drugs on effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta‐analysis	9
Exposure–response analysis of acalabrutinib and its active metabolite, ACP‐5862, in patients with B‐cell malignancies	9
Exposure–response relationships of mirvetuximab soravtansine in patients with folate receptor‐α‐positive ovarian cancer: Justification of therapeutic dose regimen	9